Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Bamlanivimab/etesevimab

Important Updates

June 25, 2021 - Distribution of bamlanivimab/etesevimab paused on a national basis until further notice.
Learn More >>

June 15, 2021 - Distribution of bamlanivimab/etesevimab paused to Rhode Island in addition to Arizona, California, Florida, Indiana, Oregon, Washington, Illinois and Massachusetts. Learn More »

May 26, 2021 - Distribution of bamlanivimab/etesevimab paused to Arizona, California, Florida, Indiana, Oregon, and Washington in addition to Illinois and Massachusetts. Learn More »

May 21, 2021 - Distribution of bamlanivimab/etesevimab is paused to Massachusetts in addition to Illinois. Learn More »

May 7, 2021 - Distribution of bamlanivimab/etesevimab is paused to Illinois. Learn More »

test

Outpatient Monoclonal Antibody Treatment for COVID-19 Made Available under Emergency Use Authorization

On February 25, 2021, Eli Lilly and Company received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the investigational monoclonal antibody treatment bamlanivimab/etesevimab. The EUA allows healthcare providers to administer bamlanivimab/etesevimab together to treat mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. In alignment with the terms of the EUA for bamlanivimab/etesevimab, the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (HHS/ASPR) will coordinate distribution of this treatment.

Direct Ordering ProcessEmergency Use AuthorizationRelated Resources

  • This page last reviewed: August 02, 2021